Guangdong Association of Clinical Trials
🇨🇳China
Clinical Trials
43
Active:1
Completed:6
Trial Phases
4 Phases
Phase 2:15
Phase 3:8
Phase 4:3
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (29 trials with phase data)• Click on a phase to view related trials
Phase 2
15 (51.7%)Phase 3
8 (27.6%)Not Applicable
3 (10.3%)Phase 4
3 (10.3%)Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma
Phase 3
Not yet recruiting
- Conditions
- Neoadjuvant Non-Small Cell Lung Cancer
- Interventions
- Other: concurrent/sequential platinum-based chemoradiotherapy
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 36
- Registration Number
- NCT06858410
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
Not Applicable
Not yet recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 342
- Registration Number
- NCT06709274
- Locations
- 🇨🇳
Dongguan People's Hospital, Dongguan, Guangdong, China
🇨🇳The First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳Guangdong Provincial People's Hostpital, Guangzhou, Guangdong, China
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Phase 4
Not yet recruiting
- Conditions
- Carcinoma, Non-Small-Cell LungBrain MetastasesLeptomeningeal Metastasis
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 50
- Registration Number
- NCT06282874
- Locations
- 🇨🇳
Guangdong Provincial Perople's Hospital, Guangzhou, Other (Non U.s.), China
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
Phase 2
Recruiting
- Conditions
- ALK Positive Non-small Cell Lung Cancer
- Interventions
- Drug: Loratinib
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 126
- Registration Number
- NCT06092086
- Locations
- 🇨🇳
Guangdong Provincial Perople's Hospital, Guangzhou, Guangdong, China
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 36
- Registration Number
- NCT05957510
- Locations
- 🇨🇳
Guangdong Provincial Perople's Hospital, Guangzhou, Guangdong, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
No news found